35
https://pubmed.ncbi.nlm.nih.gov/38116060
NLRP3/IL-1β inhibition enhances oxaliplatin efficacy in overcoming resistance and reshaping the immunosuppressive microenvironment in hepatocellular carcinoma.
“NLRP3/IL-1β Inhibition Improves Oxaliplatin Efficacy in Hepatocellular Carcinoma: Overcoming Resistance and Reshaping Immunosuppressive Microenvironment”
